NEW YORK, August 25, 2026, 09:52 EDT
- Autonomix stock was at $8.19, rising 52.51%, at 09:50:42 EDT.
- The warrant exercise of $4.9 million amounts to roughly 142% of cash on hand in June.
- Replacement warrants account for 25% more shares compared to the exercised block.
Shares of Autonomix Medical, Inc. NASDAQ: AMIX surged 52.51% on Tuesday following a $4.9 million warrant exercise that provided the pre-revenue device maker with additional funds.
The main concern for investors is not the initial stock surge, but whether the influx of capital compensates for the significant rise in possible share dilution.
AMIX was last seen at $8.19 as of 09:50:42 EDT, with 11.0 million shares changing hands—roughly 2.8 times its three-month daily average volume. The market capitalization stood at $7.95 million.
An investor has committed to exercising warrants covering 857,462 shares at a price of $5.75 per share. Autonomix anticipates receiving approximately $4.9 million in gross proceeds, prior to deduction of fees. The transaction is scheduled to close near August 26.
The transaction includes a second component. Autonomix will create two additional warrant series for 1,071,826 shares, priced at $6.25 each. This represents 125% of the number of shares exercised.
| Capital item | Shares | Price | Potential gross cash |
|---|---|---|---|
| Immediate warrant exercise | 857,462 | $5.75 | Roughly $4.9 million |
| New Series E-1 warrants | 535,913 | $6.25 | Estimated $3.35 million |
| New Series E-2 warrants | 535,913 | $6.25 | Estimated $3.35 million |
The proceeds are significant compared to Autonomix’s balance sheet. As of June 30, the company reported $3.46 million in cash and spent $3.5 million on operations in the quarter.
Management projected an additional $25 million to $30 million in funding requirements through to commercialization. The company also indicated there is significant uncertainty over its ability to continue operating as a going concern.
The funding shortfall accounts for the market’s conflicting calculations. The agreement enables further development. However, the 857,462 exercised shares represent about 88% of the 971,043 shares listed as outstanding on August 6.
The business is still in the investigational stage. Autonomix is working on a catheter-based microchip array that detects nerve signals and directs radio-frequency ablation. The company recorded no revenue for the June quarter.
| Coverage snapshot | Recommendation | Price target | Last update |
|---|---|---|---|
| Maxim Group / Anthony Vendetti | Buy | $42 | June 2, 2026 |
| S&P Global poll, two analysts | Consensus buy | $58.80 average | June 2, 2026 |
Analyst price targets provide restricted insight in this case. Coverage is limited, and the most recent targets were released before this warrant package.
Risks: The deal remains subject to closing conditions. Additional equity financing, exercise of warrants, clinical timing issues or setbacks in regulation could dilute shareholders or weigh on the stock.
Tuesday’s gains reflect an emphasis on immediate liquidity. The following challenge is if Autonomix can turn that cash into milestones before requiring further funding.
